Showing 1 to 3 of 3 results


Grifols Stock Soars After Rejecting Brookfield Takeover Bid
Grifols' stock price jumped 8.99% to €13.51 after announcing its return to dividend payments and improved 2025 cash flow guidance, exceeding Brookfield's rejected €6.45 billion takeover bid from November 2024 by €1.85 billion in market capitalization.
Grifols Stock Soars After Rejecting Brookfield Takeover Bid
Grifols' stock price jumped 8.99% to €13.51 after announcing its return to dividend payments and improved 2025 cash flow guidance, exceeding Brookfield's rejected €6.45 billion takeover bid from November 2024 by €1.85 billion in market capitalization.
Progress
40% Bias Score


Failed Buyouts Leave Grifols and Rovi to Pursue Independent Strategies
In 2024, proposed acquisitions of Grifols (valued at over €6.45 billion) and Rovi's CDMO business (valued at approximately €3 billion) failed due to valuation issues; both companies will continue operating independently.
Failed Buyouts Leave Grifols and Rovi to Pursue Independent Strategies
In 2024, proposed acquisitions of Grifols (valued at over €6.45 billion) and Rovi's CDMO business (valued at approximately €3 billion) failed due to valuation issues; both companies will continue operating independently.
Progress
36% Bias Score

Grifols Reports Record Revenue, Plans Dividend Resumption
Grifols, a Spanish pharmaceutical company, reported record 2024 revenue of €7.2 billion, exceeding expectations, and plans to resume dividend payments in 2025 while focusing on debt reduction; the company also appointed its first female president, Anne-Catherine Berner.

Grifols Reports Record Revenue, Plans Dividend Resumption
Grifols, a Spanish pharmaceutical company, reported record 2024 revenue of €7.2 billion, exceeding expectations, and plans to resume dividend payments in 2025 while focusing on debt reduction; the company also appointed its first female president, Anne-Catherine Berner.
Progress
44% Bias Score
Showing 1 to 3 of 3 results